Virtual Library

Start Your Search

Ullas Batra

Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      135P - EGFR & PD L1: An (im)perfect union (ID 566)

      12:30 - 13:00  |  Presenting Author(s): Ullas Batra

      • Abstract


      EGFR inhibitors are associated with durable responses in patients harboring EGFR mutations. Also, Immune checkpoint inhibitors are associated with higher response rates with increasing PDL1 levels. PDL1 positivity in EGFR mutant metastatic non small cell lung cancer(mNSCLC) is known to portend poor prognosis due to resistance to TKI. However, the data regarding the same is scarce. This study was done as a retrospective analysis of treated cases of EGFR mutant mNSCLC with PDL1 levels done on the archival biopsy (first biopsy) specimen, which was used for diagnosis.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      The study was conducted on 121 NSCLC patients who had previously been diagnosed with EGFR mutation by RT PCR method. PDL1 testing was carried out by SP 263 kit.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      The median age of presentation was 57 years, and 47% (n = 57) patients were aged 40-60 years. There were with 55 % males (n = 67), 86 % (n = 104) of all patients were non smokers. PDL1 was positive in 38.8 % (n = 47) patients, with 12.4 % (n = 15) patients having PDL1 ≥ 50%. PDL1 positivity was not significantly different among gender, smoking status or age or various EGFR mutations. Of all the patients, 15 patients did not take therapy. So survival analysis was possible only for 106 patients. Progression free survival (PFS) for PDL1 negative patients was 11 months (95% C.I. 8.6-13.6 months), while for PDL1 positive patients was 13 months (95% C.I. 6.3-19.6 months) p = 0.986 (not significant). The analysis also showed that PFS in patients with PDL1 positive with DEL 19 mutation was 15 months v/s7 months in L858R mutation(p = 0.09). In PDL1 negative patients, PFS was 12 months v/s 10 monthsin Del 19 v/s L858R mutation.

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      The present study showed a higher PDL1 positivity rate in EGFR mutant patients than what is previously reported. Also, the median PFS was not stastically different in PDL1 negative vs PDL1 positive patients. This is in contradiction to data previously presented. However, it could also be due to the fact that most of our patients were non smokers and could also represnt a geographic variation in PDL1 expression. Further studies are warranted to clarify this data.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      Ullas Batra, Sunil Pasricha.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.